Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.
(Stock Code: 383)

## CLARIFICATION ANNOUNCEMENT PROPOSED RIGHTS ISSUE ON THE BASIS OF ONE (1) RIGHTS SHARE FOR EVERY TWO (2) SHARES HELD ON THE RECORD DATE

Reference is made to the announcement of China Medical \& HealthCare Group Limited (the "Company") dated 5 May 2023 relating to the proposed rights issue (the "Announcement"). Capitalised terms used herein shall have the same meaning as those defined in the Announcement unless specified otherwise.

The Company hereby clarifies that the Rights Issue will result in a theoretical dilution effect (as defined under Rule 7.27B of the Listing Rules) of approximately $5.7 \%$, which is calculated based on the theoretical diluted price of approximately HK $\$ 1.0$ per Share and the benchmarked price (as defined under Rule 7.27B of the Listing Rules) of HK\$1.06 per Share.

Save for the above, other information contained in the Announcement remains unchanged.

By Order of the Board<br>China Medical \& HealthCare Group Limited<br>Chong Sok Un<br>Deputy Chairman

Hong Kong, 9 May 2023

As at the date of this announcement, the Directors comprise:-

## Executive Directors

Ms. Chong Sok Un (Deputy Chairman), Mr. Kong Muk Yin, Mr. Guo Meibao and Mr. Zhou Haiying

Non-Executive Directors
Mr. Lai Hin Wing Henry Stephen and Mr. Gao Zhaoyuan
Independent Non-Executive Directors
Mr. Zhang Jian, Dr. Xia Xiaoning, Dr. Wong Wing Kuen, Albert and Ms. Yang Lai Sum, Lisa

